Thromb Haemost 1999; 81(03): 407-414
DOI: 10.1055/s-0037-1614487
Review Article
Schattauer GmbH

Solvent Effects on Activity and Conformation of Plasminogen Activator Inhibitor-1

P. A. Andreasen
1   From the Department of Molecular and Structural Biology, Aarhus University, Denmark
,
R. Egelund
1   From the Department of Molecular and Structural Biology, Aarhus University, Denmark
,
S. Jensen
1   From the Department of Molecular and Structural Biology, Aarhus University, Denmark
,
K. W. Rodenburg
1   From the Department of Molecular and Structural Biology, Aarhus University, Denmark
› Author Affiliations
This work was supported financially by the Danish Cancer Society, the Danish Heart Foundation, the Danish Medical Research Council, the Danish Biotechnology Programme, Aarhus University Research Foundation, and the NOVO-Nordisk Foundation.
Further Information

Publication History

Received22 July 1998

Accepted after resubmission18 November 1998

Publication Date:
09 December 2017 (online)

Summary

We have studied effects of the solvent composition on the activity and the conformation of human plasminogen activator inhibitor-1 (PAI-1) from HT-1080 fibrosarcoma cells. Non-ionic detergents, including Triton X-100, reduced the inhibitory activity of PAI-1 more than 20-fold at 0° C, but less than 2-fold at 37° C, while glycerol partly prevented the detergent-induced activity-loss at 0° C. The activity-loss was associated with an increase in PAI-1 substrate behaviour. Evaluating the PAI-1 conformation by proteolytic susceptibility of specific peptide bonds, we found that the V8-proteinase susceptibility of the Glu332-Ser333 (P17-P16) bond, part of the hinge between the reactive centre loop (RCL) and β-strand 5A, and the endoproteinase Asp-N susceptibility of several bonds in the β-strand 2A-α-helix E region were increased by detergents at both 0 and 37° C. The susceptibility of the Gln321-Ala322 and the Lys325-Val326 bonds in β-strand 5A to papain and trypsin, respectively, was increased by detergents at 0° C, but not at 37° C, showing a strict correlation between proteinase susceptibility of β-strand 5A and activity-loss at 0° C. Since the β-strand 2A-α-helix E region also showed differential susceptibility to endoproteinase Asp-N in latent, active, and reactive centre-cleaved PAI-1, we propose that a detergent-induced conformational change of the β-strand 2A-α-helix E region influences the movements of β-sheet A, resulting in a cold-induced conformational change of β-strand 5A and thereby an increased substrate behaviour at low temperatures. These results provide new information about the structural basis for serpin substrate behaviour.

 
  • References

  • 1 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
  • 2 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
  • 3 Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. A review. Int J Cancer 1997; 72: 1-22.
  • 4 Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
  • 5 Huber R, Carrell RW. Implications of the three-dimensional structure of α1-antitrypsin for structure and functions of serpins. Biochemistry 1989; 28: 8951-66.
  • 6 Carrell RW, Stein PE. The biostructural pathology of the serpins: critical functions of sheet opening mechanism. Biol Chem Hoppe-Seyler 1996; 377: 1-17.
  • 7 Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
  • 8 Wilczynska M, Fa M, Ohlsson I P, Ny T. The inhibition mechanism of ser-pins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270: 29652-5.
  • 9 Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 1998; 37: 6375-9.
  • 10 Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-protease complex formation. Proc Natl Acad Sci USA 1997; 94: 453-8
  • 11 Wilczynska M, Fa M, Karolin J, Ohlsson PI, Johansson LBÅ, Ny T. Struc tural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol 1997; 4: 354-7.
  • 12 Stein PE, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-21.
  • 13 Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA. Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-center-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-85.
  • 14 Plotnick I M, Mayne L, Schechter NM, Rubin H. Distortion of the active site of chymotrypsin complexed with a serpin. Biochemistry 1996; 35: 7586-90.
  • 15 Kaslik G, Patthy A, Bálint M, László G. Trypsin complexed with α1-proteinase inhibitor has an increased structural flexibility. FEBS Lett 1995; 370: 179-83.
  • 16 Kaslik G, Kardos J, Szabo E, Szilagyi L, Zavodszky P, Westler WM, Markley JL, Graf L. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 1997; 36: 5455-64.
  • 17 Stavridi ES, O´Malley K, Lukacs CM, Moore WT, Lambris JD, Christianson DW, Rubin H, Cooperman BS. Structural change in α-chymotrypsin induced by complexation with α1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 1996; 35: 10608-15.
  • 18 Gils A, Declerck PJ. Modulation of plasminogen activator inhibitor 1 by Triton X-100. Identification of two consecutive conformational transitions. Thromb Haemost 1998; 80: 286-91.
  • 19 Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen activator inhibitor-1. Eur J Biochem 1996; 241: 38-46.
  • 20 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
  • 21 Kjøller L, Kanse SM, Kirkegaard T, Rodenburg KW, Rønne E, Goodmann SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
  • 22 Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity, determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
  • 23 Grøndahl-Hansen J, Nielsen LS, Kristensen P, Grøndahl-Hansen V, Andreasen PA, Danø K. Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 1985; 113: 257-63.
  • 24 Urano T, Strandberg L, Johansson LBÅ, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Eur J Biochem 1992; 209: 985-92.
  • 25 Helenius A, Simons K. Solubilization of membranes by detergents. Biochim Biophys Acta 1975; 415: 29-79.
  • 26 Gekko K, Timasheff SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 1981; 20: 4667-76.
  • 27 Gekko K, Timasheff SN. Thermodynamic and kinetic examination of protein stabilization by glycerol. Biochemistry 1981; 20: 4677-86.
  • 28 Hubbard SJ, Eisenmenger F, Thornton JM. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Science 1994; 3: 757-68.
  • 29 Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-8.